Taken together, our results lend support to the novel hypothesis that PSGs exert sex-specific effects on tumor-immune cell crosstalk and cancer outcomes, suggesting that PSGs could be drug targets for ~30% of female LUAD patients with PSG expression. Here, PSG5 is linked to neoplasm.